CVT And Gilead Look To Lock Out Astellas With Planned Merger
Market reaction was mixed but CV Therapeutics and Gilead threw a shock into the current pharma/biotech merger and acquisition frenzy as Gilead sought to trump Astellas' months-long bid to acquire CVT with its own bid of $20 per share. The deal's estimated total value is $1.4 billion
You may also be interested in...
Dominant in HIV, the biotech pays $375 million up front for Seattle-based Calistoga and its closely-watched PI3K program.
The hedge fund operator offers $154 million after Cypress' unpopular licensing of an anti-psychotic drug. But Ramius might want to share the upside on the drug after all.
Appointment of leading hepatitis C expert from Duke to senior VP-liver disease therapeutics reaffirms Gilead's commitment to expanding into hepatitis C.